Abstract Mutations of the nucleophosmin (NPM-1) gene have been reported in 50-60% of acute myeloid leukemia (AML) patients with normal karyotype. This work was designed to study the prevalence and nature of NPM1 gene mutations in a group of Egyptian patients with AML to get an idea about the profile of NPM1 gene mutations in our society. In 45 previously untreated patients with de novo AML, peripheral blood and/or bone marrow samples from all patients were subjected to microscopic morphologic examination, cytochemical analysis, immunophenotyping and karyotyping. Patients with normal cytogenetic results were selected for molecular analysis of NPM1 exon 12 by PCR amplification followed by DNA sequencing of the amplified product. Twenty-one patients (46.7%) had abnormal karyotype: six cases with t(15; 17), five cases with
Introduction
Acute myeloid leukemia (AML) describes a group of hematopoietic stem cell disorders characterized by the expansion of undifferentiated myeloid progenitors [1] . AML is a heterogeneous group of neoplastic disorders with great variability in clinical course and response to therapy as well as in the genetic and molecular basis of their pathology [2] .
Major advances in the understanding of leukemogenesis have been made by the characterization and the study of acquired cytogenetic abnormalities particularly reciprocal translocations observed in AML. Beside these major cytogenetic abnormalities, gene mutations also constitute key events in AML pathogenesis [3] .
The World Health Organization (WHO) classification of AML incorporates clinical, morphologic, immunophenotypic and genetic features in an attempt to define entities that are biologically homogeneous and have clinical relevance. The classification encompasses four major categories: AML with recurrent genetic abnormalities, AML with multilineage dysplasia, AML that is therapy related, and AML not otherwise categorized [4] .
Almost 45-50% of AML patients have no detectable chromosomal abnormalities [5] . The clinical and biologic features of this large cytogenetic subgroup are still poorly understood. Accordingly, most of these cases are classified in the WHO scheme under the term ''acute myeloid leukemia not other wise characterized'' [6] .
Stefan et al. [7] reported that in most cases of AML conventional cytogenetic study reliably detects chromosomal abnormalities and this method should not be replaced by fluorescent in situ hybridization (FISH). FISH should be used as a complementary method for the detection of more subtle abnormalities. Furthermore, molecular cytogenetics using a comprehensive set of DNA probes provides a valuable diagnostic tool for patients with poor chromosome morphology, low or no yields of metaphase cells.
Cytogenetic aberrations have been recognized as the most important prognostic variable in AML. In recent years, there has been growing interest in moving beyond cytogenetics to subsets of AML with molecular aberrations (i.e. mutated or abnormally expressed genes) that can be used for further stratification of AML patients [8] .
Mutations of the nucleophosmin (NPM1) gene have been reported in 50-60% of AML patients with normal karyotype [5] . Andersen et al. [9] reported that frame shift mutations of NPM1 gene were the frequently occurring abnormality in patients with de novo AML. Scholl et al. [10] mentioned that NPM1 mutations were associated with favorable prognosis in younger AML patients, mostly when not associated with Flt-3 mutations.
The nucleophosmin (NPM1) gene contains 12 exons, it was mapped in humans to chromosome 5q35. The NPM1 is translocated or mutated in various lymphomas and leukemias, forming fusion proteins or NPM1 mutant-products. The nucleophosmin (NPM1) gene encodes a multifunctional nucleocytoplasmic shuttling protein that is localized mainly in the nucleolus [11] .
NPM1 protein has several functions among which are the biogenesis of ribosomes and the control of centrosome duplication [12] . NPM1 protein prevents protein aggregation in the nucleolus [13] .
Analysis of mutated NPM1 gene has important clinical and pathologic applications. Immunohistochemical detection of cytoplasmic NPM1 protein predicts NPM1 gene mutations and helps rationalize cytogenetic/molecular studies in AML. Due to their frequency and stability, NPM1 mutations may become a new tool not only for risk stratification of AML patients at time of diagnosis, but also for monitoring minimal residual disease (MRD) during and after the course of therapy in AML with normal karyotype [14] . The use of genetic markers to detect MRD allows targeting therapy to appropriate patients by identifying patients at high risk of relapse and treating them aggressively. It also identifies patients for whom aggressive therapy is not necessary, thus reducing both cost and unnecessary treatment intervention [15] .
As a result of the importance of detecting NPM1 gene mutations in AML patients with normal karyotype, this work was designed to study the prevalence and nature of the NPM1 gene mutations in AML patients within an Egyptian group (our study population) to get an idea about the profile of NPM1 gene mutations in our society.
Patients and methods
The present study was carried out on 45 untreated newly diagnosed patients who presented to Kasr El-Aini Center of Clinical Oncology & Nuclear Medicine, Suez Canal University Hospital and Maadi Armed Forces Hospital.
Inclusion criteria
Newly diagnosed AML patients, with no previous treatment, were included in the study. Patients with normal karyotype were selected for molecular analysis.
Exclusion criteria
Patients with history of exposure to chemotherapy/radiotherapy, and secondary AML patients, were excluded from our study.
After patient informed consent and approval from the institutional review board, the following laboratory work-up was done for all patients: peripheral blood examination (CBC: Hb level, WBCs count, platelet count and blast cells%), bone marrow examination, immunophenotyping for myeloid lineage (CD13, CD14, CD15, CD19, CD33, CD34 and CD64) and cytochemical analysis of WBCs by Sudan Black .
Four milliliters (ml) of peripheral blood were collected and divided into two vacutainers, 2 ml on heparin for cytogenetic analysis, 2 ml on EDTA for DNA extraction and molecular analysis. The 45 patients enrolled in the study were subjected to cytogenetic analysis; patients with normal cytogenetic results were selected for molecular analysis of NPM1 exon by PCR amplification followed by DNA sequencing of the amplified product.
Cytogenetic analysis was performed after 72 h of synchronized culture. Karyotypes were analyzed after G banding. Chromosomal abnormalities were described according to the International System of Human Cytogenetic Nomenclature (ISCN). Patients with normal cytogenetic results were selected for molecular analysis.
Analysis of NPM1 exon 12 mutations
Genomic DNA was isolated from mononuclear cell preparations stored at À70°C using the DNA extraction kit (Qiagen, Germany) according to the manufacturer's instructions.
Polymerase chain reaction (PCR) amplification of NPM1 exon 12 was carried out using specific primers: NPM1-F in intron 11 (5 0 -TTAACTCTCTGGTGGTAGAATGAA-3 0 ) and NPM1-R in the 3 0 flanking region (5 0 -CAAGACTATTTGC-CATTCCTAAC-3 0 ). The PCR mixture (50 ll) contained $100 ng DNA, 10 pmol of each primer, 10 mM each dNTPs, 2.5 U Gold Taq polymerase, and the supplied buffer (Applied Biosystems, Darmstadt, Germany). The PCR conditions were as follows: 95°C for 5 min; 40 cycles of 94°C for 30 s; 55°C for 1 min; 72°C for 1 min.
PCR products were purified by standard methods and directly sequenced using the ABI Ready Reaction DyeTerminator Cycle Sequencing Kit (Applied Biosystems).
For the sequencing reaction, the following was added to a PCR tube (20 ll): Terminator ready reaction mix (4.0 ll), DNA template (2-5 ll), 1 ll primer (forward or reverse). The cycle sequence was carried on ABI 310 for 25 cycles: denaturation at 96°C for 3 min followed by a 3-step PCR of 96°C for 10 s, 50°C for 5 s, 60°C for 4 min. The reaction was held at 4°C until purification. Purification was done using DyeEx Columns (Cat. No. 63104-Qiagen). Samples were resuspended in 30 ll TSR (Cat. No. 401674-ABI) and the sequence analysis was done using capillary reaction (Cat. No. 402840-ABI).
Statistical analysis
Data were presented as median and range or mean ±SD values. The non-parametric t-test was used for comparing means of independent groups. The Chi-square and Fisher exact tests were used for comparing proportions. P-value was considered significant at the 0.05 level. Statistical analysis was performed using the SPSS 14.0 software for WindowsÒ.
Results
Forty-five previously untreated patients with de novo AML were included in this study. Males constituted 33.3% of this group, females 66.7%. The patients' ages ranged from 17 to 60 years. The clinical characteristics of these patients are illustrated in Table 1 . Twenty-four patients out of the 45 (53.3%) had normal karyotype, while 21 (46.7%) had abnormal karyotypes. Patients with normal karyotypes were subjected to molecular analysis.
Cytogenetic analysis results
About 53.3% of the study population had normal karyotype. Of the 45 studied patients, 46.7% had abnormal karyotype with 5 different types of abnormalities detected. Six cases had t(15; 17), five cases t(8; 21), five cases trisomy 8, two cases inv(3), and three cases had monosomy 7 (Table 1) . 
Molecular analysis results
Twenty-four patients in the present study showed normal karyotype. The demographic data of these patients is shown in Table 2 . DNA sequencing was done for these patients. Sequence analysis revealed that 11 patients (45.8%) harbored mutant NPM1; 2 cases showed type A mutation (Fig. 1 In the present study, the rest of the translocations were trisomy 8 in three patients, monosomy 7 in three patients, and inv(3) in the remaining two patients. Trisomy 8 was more frequent in our study compared to the results of Bahjati et al. [16] . Association between trisomy 8 and leukemia may be due to the higher expression of ETO gene due to increased copies of chromosome 8.
In the present study, cytogenetic analysis of 45 patients with de novo AML revealed that 24 patients (53.3%) had normal karyotype, which is consistent with Garzon et al. [18] who recorded an AML-NK prevalence of 50%. Meanwhile, it is slightly higher than that recorded by Schnittger et al. and Frohling et al. (45%) [6, 19] , while it is lower than that recorded by Alcalay et al. (89.6%) [20] , putting into consideration that our study population is limited compared to their population.
Sequence analysis of the NPM1 gene exon 12 revealed that 11 of 24 patients (45.8%) with normal cytogenetics harbored NPM1 exon 12 mutations. In spite of the difference between the used methods in our study and those used by Boissel et al. [13] , PCR amplification of exon 12 and fragment analysis by denaturing polyacrylamide gel electrophoresis, the prevalence is almost equal in both studies (45.8% and 47%, respectively).
A similar prevalence was reported in a cohort study of 300 patients by Dohner et al. [21] However, the prevalence in our study is higher than that recorded by Thiede et al. [1] who compared the effectiveness of direct sequencing of NPM1 gene and Figure 1 Sequencing of PCR amplified sequence (NPM1 gene, exon12) indicates mutation type A. the gene scan method detection of NPM1 mutations in a larger number of patients with de novo AML.
In the present study, sequencing of exon 12 revealed three types of mutations. The first observed mutation was type A mutation (ins 1015-1019) (TCTG). It was detected in only 2 patients (18%). This result was consistent with those of Falini et al. [22] who recorded mutation A in AML patients with normal karyotype. However, our prevalence is lower than that reported by Schnittger et al. (78.3%) [6] and Dohner et al. (76.0%) [21] . The discrepancy between previous results may be due to the large difference in the number of study population) 166 patients in Schnittger study, 300 patients in Dohner study, 45 patients in our study).
The second detected mutation was insertional mutation (ins 1015-1019) (CACG) associated with point mutation (1006 C>G), which was not consistent with any of the documented mutations. This type of mutation was found in only 2 patients (18%), and up to our knowledge, it is the first time to identify this type of mutation in Egyptians. The region of exon 12 preceding this insertion was heterozygous frame shift, while it was corrected just after the insertion site. The explanation of this finding may be due to the insertion of bases in a number which is not a multiple of three in intron 11, resulting in frame shift extending along exon 12 till the mutation A(TCTG insertion) that balances the effect of the previous mutation.
The third detected mutation was deletion of one base only, or associated with point mutation, in 7 patients (63.3%). The cases with frame shift in the site preceding the deletion were most probably insertional deletion mutation, because frame shift was corrected just after the deletion site. This result was not in consistence with most of the recorded mutations, which were in most cases insertional mutations. However, it goes along side with the finding mentioned by Chen et al. [4] who detected a single base pair deletion (del T1146) in the untranslated region of exon 12.
The detected NPM1 mutations were found to be associated with specific parameters (age, sex, CBC, immunophenotyping of myeloid cells and FAB subtypes) .In our study, there was no significant difference between mutant NPM1 and wild type gene, regarding the sex and age. This is in agreement with Boissel et al. [20] who did not find significant association between mutant NPM1, age and sex. Also Falini et al. and Dohner et al. [21, 22] found that mutant NPM1 was not associated with age, but they found a correlation between mut NPM1 and female sex.
We found association between mutant NPM1 and myelomonocytic morphology (FAB M4/M5), however no association was found with M0, M1, M2, M3. These findings are in accordance with the observed association of mutant NPM1 with M4 and M5 but not with other FAB subtypes reported by Boissel et al. and Dohner et al. [13, 21] . There was no significant difference between mutant NPM1 and wild type patients at the time of presentation in terms of white blood cell count, hemoglobin level, platelet count and percentage of peripheral blood blasts, in our study. Also Cazzaniga et al. [23] did not find significant association between mutant NPM1 and WBC count at the time of presentation, but Chen et al. [4] stated that mutant NPM1 genes tend to have higher white blood cell count and higher bone marrow blast percentage than AML patients carrying wild type NPM1 gene. Also Dohner et al. [21] found that mutant NPM1 was associated with higher WBC and platelet count and higher percentage of bone marrow blasts.
Immunophenotyping of myeloid cells in our study population showed higher expression of CD13, CD33 and CD64 in the mutant NPM1 gene than in wild type NPM1 and lower expression of CD14 and CD15 in the mutant NPM1 with negative expression of CD34 in these cases.These findings are consistent with the findings documented by Chen et al. [4] . They stated that mutant NPM1 gene mutation patients showed absence of the hematopoietic stem cell marker CD34. Our findings are also in accordance with the results of Cazzaniga et al. [23] who reported that children with AML and NPM1 mutation were CD34 negative at diagnosis.
In conclusion, our study results showed that NPM1 gene mutations are not related to age or sex, more frequently associated with myelomonocytic phenotype, associated with high CD13, CD33 and CD64, negative CD34 expression and not associated with WBC and platelet count.
The exact frequency and the prognostic relevance of the novel NPM1 mutations reported in this study warrants a larger study in Egypt and other areas of similar ethnic and environmental backgrounds.
